Sector Expert: Douglas Loe

Leede Jones Gable

Image: Douglas Loe

Douglas Loe, managing director and analyst at Leede Jones Gable, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors. Loe has been recognized as one of Canada's top healthcare analysts by the StarMine Analysts Awards, based on the quality of his recommendations to institutional investors. He holds a Ph.D. in biochemistry.



Recent Quotes

"We are initiating coverage on PMN with a Speculative Buy rating."

— Douglas Loe, Leede Jones Gable (5/11/22)
more >

"Liquidity metrics in Q2/18 indicated RP exited with cash of $48.8K."

— Douglas Loe, Echelon Wealth Partners (9/6/18)
more >

"RP signed on its licensing and codevelopment deal with YOFOTO."

— Douglas Loe, Echelon Wealth Partners (7/12/18)
more >

"IMV is revising its capital structure through a share consolidation."

— Douglas Loe, Echelon Wealth Partners (5/3/18)
more >

"IMV expanded its collaboration with Incyte with another Phase 2 trial."

— Douglas Loe, Echelon Wealth Partners (4/24/18)
more >

"IMV is presenting preclinical data at the AACR meeting this week."

— Douglas Loe, Echelon Wealth Partners (4/16/18)
more >

"As in Q4/17 and in Q1/18, we are ascribing Top Pick status to IMV."

— Douglas Loe, Echelon Wealth Partners (4/3/18)
more >

"The ovarian cancer trial of IMV's DPX-Survivac is nearing completion."

— Douglas Loe, Echelon Wealth Partners (3/28/18)
more >



Due to permission requirements, not all quotes are shown.